spacer
home > ict > autumn 2018 > planning and execution
PUBLICATIONS
International Clinical Trials

Planning and Execution

Japan presents some unique challenges and complexities when it comes to the management of both clinical trial and marketed product pharmacovigilance (PV). The Japan Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA) have safety reporting requirements that differ significantly from EU and US standards. This article will discuss the key considerations for developing a PV group in Japan that includes the right procedures, timelines, and systems, but, most of all, the right team.

Individual Case Safety Report (ICSR) Processing

The enforcement regulations of the Pharmaceutical and Medical Device Act stipulates the provisions of reporting ICSRs, as indicated in Tables 1-4. A key difference from EU and US standards is the PMDA requirement to report measures taken overseas for medicinal products containing the same API and research reports. Measures taken overseas require review of regulatory authority websites to identify any ICSRs that meet the criteria (see Table 3). Typically, the process of searching these websites is subcontracted to a local vendor, which provides a daily email of potential measures taken overseas with the PV team reviewing these outputs to confirm whether the criteria has been met. Research reports involve searching both local and global scientific literature databases based on preagreed search strings and then reviewing the outputs to identify any ICSRs that meet the criteria (see Table 4, page 29).

Additionally, reporting certain adverse drug reactions (ADRs) assessed as expected against the current reference safety information (RSI) is needed; this is also a departure from EU and US standards.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gary Barker joined PPD’s PV department in 2005 and has spent time in Singapore and Australia developing the company’s capabilities in Asia-Pacific. He is accountable for clinical trial and marketed product PV across Asia-Pacific Eastern Europe and projects in North America.

April Pierce joined PPD in 2000 and has served the majority of her tenure in operational management of global projects. Currently, her primary role is providing oversight of the PV strategic proposal development group for both clinical trials/ marketed projects and managing PV’s budget operational staff.

Dr Yasmine Chiu joined PPD in 2012 and is a member of the company’s medical monitor senior management team. She is responsible for medical monitoring oversight for clinical trials across Asia-Pacific, including Japan and China.

Yasumasa Kurioka joined PPD-SNBL as General Manager in 2015. He is responsible for all clinical functions at PPD-SNBL in Japan. He has more than 25 years of experience with both CRO and pharma companies.

Tsutomu Yonehana joined the PPD-SNBL PV department in 2018. He has worked in PV roles of responsibility for 20 years. Most recently, he served as Senior Safety Manager at Celgene Japan where he was responsible for the oversight of all PV activities for sponsored clinical trial and marketed product programmes.
spacer
Gary Barker
spacer
spacer
spacer
April Pierce
spacer
spacer
spacer
Dr Yasmine Chiu
spacer
spacer
spacer
Yasumasa Kurioka
spacer
spacer
spacer
Tsutomo Yonehana
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Envigo launches PATHWAY an optimized safety assessment solution to enable first in human clinical trials

11 March 2019, East Millstone, N.J. – Envigo, a leading provider of non-clinical contract research services and research models, announced today the launch of PATHWAY – an integrated solution that optimizes non-clinical safety assessment programs to enable first-in-human clinical trials. PATHWAY is designed to manage the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers by integrating safety assessment study types and bioanalytical support with scientific and regulatory consulting, program design and project management.
More info >>

White Papers

BioT ULT Transporter

BioCision

The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

 
Industry Events

ASGCT 22nd Annual Meeting

29 April - 2 May 2019, Washington Hilton, Washington, D.C

The 2019 ASGCT Annual Meeting is expected to be the largest in Society history, eclipsing the mark set by the 2018 meeting just last year. Join more than 3,500 researchers, clinicians, advocates, and industry leaders in discovering the latest science and technology surrounding gene and cell therapy.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement